Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | RBP4 | P02753 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165261 | 0.94 | SHMT2 (0.35) | SHMT2GAAMEN1KMT2AKDM4E | |
| Trifluoroacetic Acid SCHEMBL167491 | 0.79 | KMT2A (0.50) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL167730 | 0.77 | MEN1 (0.57) | MEN1KMT2AKDM4ELMNAMAPT | |
| Trifluoroacetic Acid SCHEMBL165260 | 0.73 | IGF1R (0.44) | GAAMEN1KMT2AKDM4ELMNA | |
| SCHEMBL15077842 | 0.71 | IGF1R (0.48) | MEN1KMT2AKDM4ELMNAMAPT | |
| SCHEMBL174473 | 0.69 | MEN1 (0.55) | GAAMEN1KMT2AKDM4EMAPT | |
| SCHEMBL173758 | 0.68 | SMN1; SMN2 (0.53) | GAAMEN1KMT2AKDM4EMAPT | |
| SCHEMBL27807412 | 0.68 | MAPT (0.51) | GAAMEN1KMT2AKDM4ELMNA | |
| SCHEMBL175118 | 0.63 | RAB9A (0.58) | GAAMEN1KMT2ALMNAMAPT | |
| SCHEMBL175262 | 0.62 | SMN1; SMN2 (0.55) | MEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611806-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Ascepion Pharmaceuticals, Inc. (CN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
| WO-2012028106-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | SHMT2 1348/4885GAA 2720/4885MEN1 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.